RPRX Fair Value — Royalty Pharma Plc

Biotechnology · Institutional-depth multi-model valuation on Equity Rank

Current Price
$56.15
Consensus Fair Value
$67.84
Margin of Safety
20.8%

When does RPRX report earnings?

Royalty Pharma Plc (RPRX) is next scheduled to report earnings on Aug 5, 2026. The consensus analyst EPS estimate for the upcoming quarter is $1.27.

Heading into this report, the model's fair value estimate sits 20.8% above the current price (model fair value differential above current price). Descriptive context only — not a forecast of the earnings result.

Earnings dates and estimates are sourced from third-party data and may change or lag. Informational only.

How RPRX's valuation models agree

Equity Rank computed model fair value for RPRX from 11 independent valuation methods with sufficient data. 6 place fair value above the current price of $56.15, and 5 place it below. The model-blended estimate lands at $67.84 — a model fair value differential of 20.8% above the current price under these model assumptions. The larger group corresponds to potential undervaluation versus the current price.

Models: FV above price
6
Models: FV below price
5
Models compared
11

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

RPRX fundamental profile

Equity Rank's fundamental strength composite scores RPRX at 67.1/100 (B, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +189.3% per year and gross margin has moved +40.3 pp. Its SAVE composite score has moved -0.2 over the past 30 days.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About RPRX

Royalty Pharma Plc (RPRX) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Stocks in Biotechnology

JNJ · UNH · PFE · ABBV · MRK

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator